Commissioned research update report
Biogen’s progress with its Alzheimer’s disease drug (aducanumab) gives support for the amyloid hypothesis and significantly strengthens AlzeCure’s case. The company’s Alzstatin-program focuses on disease-modifying therapies for early Alzheimer’s disease by reducing the production of amyloid beta. It also offers several advantages over some of the more advanced peers such as BioArctic’s BAN2401 and Biogen’s aducanumab. We expect that future progress and generation of satisfactory data will drive the stock price and trigger an elevated company valuation.
Marketing material commissioned by AlzeCure Pharma